id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-316534-ep7ezoko	Gamble, Lena J	Current progress in the development of a prophylactic vaccine for HIV-1	2010-12-22		.txt	text/plain	11945	631	40	67 The vaccine, a recombinant adenovirus serotype 5 (Ad5) virus incorporating the gag, pol, and nef genes from HIV-1, had been previously tested in an SHIV model in macaques and the results of that experiment were not suggestive of the results of the human trial. In hopes of creating a vaccine which elicits sterilizing immunity to HIV-1, researchers have focused their efforts on (1) the use of plasmid DNA vaccines, (2) live recombinant vectors for vaccine development (expressing or presenting HIV antigens), and (3) mucosal immunity. For instance, research performed by Harari and colleagues in 2008 demonstrated that vaccination by means of an HIV-1 clade C DNA prime in combination with a pox vector (NYVAC) boost induces a reliable polyfunctional and longlasting anti-HIV T-cell response in human participants. Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the T cell proliferative response	./cache/cord-316534-ep7ezoko.txt	./txt/cord-316534-ep7ezoko.txt